Search Results

HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS ® Selected Advanced Solid Tumors.

HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603.

HiFiBiO Therapeutics announced today a second clinical trial supply agreement with Novartis to evaluate HiFiBiO’s HFB200603, a novel anti-BLTA monoclonal antibody in combination with tislelizumab, Novartis anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS™) platform.

FibroGen, Inc. and HiFiBiO Therapeutics announced an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program.

HiFiBiO Therapeutics announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO’s HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications.

FibroGen, Inc. and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.

HiFiBiO Therapeutics today announced the completion of an oversubscribed $75M Series D financing round.

HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody HFB30132A possesses differentiated properties providing strong potential for COVID-19 treatment and prevention